Scientific Perspectives October 19, 2026

Galderma and ZO: Building a Business Around Skin

Galderma’s agreement to acquire ZO Skin Health illustrates how prescription treatments, aesthetics and daily care can fit within one skin-health business.

skin health
dermatology
industry strategy

The skin-health business behind a $1.5 billion agreement

A dermatology medicine, an aesthetic treatment and a daily skin-care regimen may serve different needs in the same person’s life. Galderma’s agreement to acquire ZO Skin Health offers a concrete view of how those businesses can connect.

In October 2026, Galderma announced an agreement to acquire ZO at an enterprise value of $1.5 billion. ZO reported approximately $330 million in net sales for the 12 months through June 2026, placing the announced enterprise value at roughly 4.5 times that sales figure. In its October 22 update, Galderma expected closing in the fourth quarter of 2026 or early 2027, subject to customary conditions. ^{[1, 2]}

At the center of the transaction is a particular relationship with the user: ZO has built a professional-channel presence around products designed for daily care.

Three businesses, three sources of value

Galderma operates across therapeutic dermatology, injectable aesthetics and dermatological skincare. In 2025, the three categories contributed $1.185 billion, $2.572 billion and $1.449 billion respectively to net sales of $5.207 billion. For the first nine months of 2026, Galderma reported $4.765 billion in net sales, up 25.1% year on year at constant currency. ^{[2, 3]}

Each business has a different economic rhythm. Prescription medicines draw on clinical development and treatment needs; aesthetic products serve appearance-related needs through professionals; daily skincare can create an ongoing product relationship through regular use. Their development, regulatory and payment requirements differ, while their focus on skin health brings them into the same broader field.

One person may receive treatment for a skin condition, seek a professional aesthetic service at another point and use skincare over time. For a company active across these areas, understanding those needs can connect professional expertise, product formats and service channels.

From professional visits to daily care

ZO sells multi-step regimens through physician, medical spa and online channels, with more than 16,500 accounts across over 40 countries. Galderma’s existing Alastin brand focuses in part on care around aesthetic procedures. Bringing the portfolios together gives Galderma an opportunity to extend its offering from professional services into daily routines. ^[1]

That relationship also helps explain the transaction price. The $1.5 billion enterprise value reflects ZO’s existing sales and Galderma’s expectations for future product development, commercial reach and growth. The company expects additional commercial investment, slight dilution to group core EBITDA margin in 2027, and a margin for the acquired business broadly comparable to the group from 2028. ^[2]

Galderma is part of a wider movement. In September 2026, AbbVie’s Allergan Aesthetics introduced AA Signature: SKIN360, a consultation and treatment-planning framework that brings the company’s injectable and professional skincare products into one assessment. ^[4]

L’Oréal, meanwhile, has invested in Galderma to participate in dermatology. Pharmaceutical and aesthetics companies are extending into ongoing care, while a beauty group is connecting with medical needs through investment and science. Their starting points differ, but the people and needs they seek to serve increasingly intersect. ^[5]

The longer-term question is how companies organize science, products and channels around needs that span treatment, professional services and everyday use.

Where technology platforms can contribute

For technology and formulation partners, that creates a concrete role. Different products may require different actives, formats and endpoints, while sharing a need to understand the skin barrier, active stability, distribution in the target area and the experience of use. A platform that combines these capabilities around a defined need can contribute at several stages, from formulation selection to human evaluation.

The Galderma–ZO agreement illustrates a model worth following: professional channels establish trust, daily products extend the relationship, and underlying technologies support the development of new products and collaborations.

Explore N1 Life’s partnership approach.

Sources

All Insights